One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases
Anneliene Hechtelt Jonker1,2 , Simon Day1,3 , Michela Gabaldo1,4 , Heather Stone1,5 , Martin de Kort1,6 , Daniel J. O’Connor1,7 & Anna Maria Gerdina Pasmooij
doi : 10.1038/d41573-023-00168-9
Volume 22 Issue 12, December 2023
Glue-based KRAS inhibitors make their debut cancer trial mark
By Asher Mullard
FDA approves C5-blocking macrocyclic peptide for autoimmune disease
By Asher Mullard
Drug developers back US$80 million African ancestry genomics initiative
By Asher Mullard
PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx
By Ana Rosa Saez-Ibañez, Erin Sommers, Samik Upadhaya & Jay Campbell
The company landscape for artificial intelligence in large-molecule drug discovery
By Navraj S. Nagra, Lieven van der Veken, Erika Stanzl, David Champagne, Alex Devereson & Matej Macak
Phosphatase inhibitor drives anticancer immune responses
By Alex Eccleston
A new shuttle for drug delivery across the blood–brain barrier
By Katie Kingwell
Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections
Ursula Theuretzbacher, Benjamin Blasco, Maëlle Duffey & Laura J. V. PiddockÂ
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Marco Ruella, Felix Korell, Patrizia Porazzi & Marcela V. MausÂ
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Christopher A. Klebanoff, Smita S. Chandran, Brian M. Baker, Sergio A. Quezada & Antoni RibasÂ
